An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment.
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Everolimus (Primary) ; Octreotide (Primary)
- Indications Endocrine gland neoplasms; Lung cancer
- Focus Therapeutic Use
- 02 Jun 2015 Status changed from recruiting to active, no longer recruiting as per results presented at the 51st Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2015 Results (4-year update) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jul 2011 New trial record